RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Transcode Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.70+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.2%
0M of 17M shares
Institutional holders
8
2 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| CK Life Sciences Int'l., (Holdings) Inc. | 83,285 | 9.10% | 13D (active) amendment | Oct 27, 2025 |
| Hal Mintz | 69,555 | 9.90% | 13G (passive) | Dec 31, 2024 |
| Thomas A. Fitzgerald | 422,036 | 5.50% | 13D (active) | Jun 21, 2024 |
| Thomas Joseph Tracy | 35,000 | 5.00% | 13D (active) | Mar 7, 2025 |
| Unleash Immuno Oncolytics, Inc. | 300,000 | 9.94% | 13G (passive) | Jul 23, 2026 |
| Elena Rosa Braci | 186,236 | 6.17% | 13G (passive) | Jul 23, 2026 |
| Daniel Eduardo Katzman | 155,611 | 5.16% | 13G (passive) | Jul 23, 2026 |
| Defj, LLC | 14,134,481 | 83.90% | 13D (active) amendment | Aug 3, 2026 |
| SC-Sigma Global Partners, LP | 101,772 | 9.90% | 13G (passive) | Apr 15, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RNAZ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Yorkville Advisors Global, LP | 19,639 | 0.12% | $121.96K | New | 0.14% |
| Vanguard Capital Management LLC | 6,545 | 0.04% | $40.64K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 2,982 | 0.02% | $18.52K | – | 0.00% |
| UBS Group AG | 2,888 | 0.02% | $17.93K | −5,407 | 0.00% |
| FMR LLC | 706 | 0.00% | $4.38K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 677 | 0.00% | $4.20K | +449 | 0.00% |
| Wells Fargo & Company/Mn | 55 | 0.00% | $342 | – | 0.00% |
| SBI Securities Co., Ltd. | 12 | 0.00% | $75 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 0.2% | 2 / 1 | 1 / 2 | 0M | 0M |
| Q1 2026 | 8 | 0M | 0.2% | 4 / 2 | 1 / 2 | 0M | 0M |
| Q4 2025 | 6 | 0M | 0.0% | 1 / 1 | 0 / 3 | 0M | 0M |
| Q3 2025 | 8 | 0M | 0.1% | 3 / 0 | 2 / 4 | 0M | 0M |
| Q2 2025 | 9 | 0M | 0.2% | 9 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RNAZ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 8,492 | 0.05% | $43.65K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 6,545 | 0.04% | $40.64K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 1,180 | 0.01% | $6.07K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 510 | 0.00% | $2.62K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -199 | -0.00% | -$1.24K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas A. Fitzgerald | Chief Financial Officer, Director | 56,318 | 0.33% | Sep 11, 2026 |
| John A. Tattory | Interim CFO | – | – | Sep 21, 2026 |
| Jack E. Stover | Director | – | – | Dec 22, 2025 |
| Elizabeth Czerepak | Director | – | – | Dec 22, 2025 |
| Life Sciences Intl (Holdings) Inc CK | 10% owner | 12,113,899 | 71.55% | Aug 5, 2026 |
| Defj, Llc | 10% owner | – | – | Aug 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Life Sciences Intl (Holdings) Inc CK 10% owner | Aug 3, 2026 | Conversion | +11,813,859 | – | – | 12,113,899 |
| Life Sciences Intl (Holdings) Inc CK 10% owner | Aug 3, 2026 | Conversion | +2,020,582 | – | – | 14,134,481 |
| Robert Michael Dudley Chief Executive Officer, Director | Sep 28, 2023 | Buy | +98,000 | $0.51 | $49.98K | 180,262 |
| Thomas A. Fitzgerald Chief Financial Officer, Director | Sep 28, 2023 | Buy | +49,350 | $0.51 | $25.17K | 56,318 |
| Robert Michael Dudley Chief Executive Officer, Director | Jun 21, 2023 | Buy | +12,000 | $2.65 | $31.80K | 82,262 |
| Robert Michael Dudley Chief Executive Officer, Director | Jun 20, 2023 | Buy | +6,607 | $2.55 | $16.85K | 70,262 |
| Robert Michael Dudley Chief Executive Officer, Director | Jun 9, 2023 | Buy | +19,000 | $2.76 | $52.44K | 61,155 |
| Robert Michael Dudley Chief Executive Officer, Director | Jun 9, 2023 | Buy | +19,000 | $2.76 | $52.44K | 912,114 |
| Robert Michael Dudley Chief Executive Officer, Director, 10% owner | Sep 14, 2022 | Buy | +20,000 | $1.15 | $23.00K | 893,114 |
| Thomas A. Fitzgerald Chief Financial Officer, Director | Jun 16, 2022 | Buy | +12,000 | $1.27 | $15.24K | 139,377 |
| Robert Michael Dudley Chief Executive Officer, Director, 10% owner | May 31, 2022 | Buy | +2,000 | $1.87 | $3.74K | 873,114 |
| Robert Michael Dudley Chief Executive Officer, Director, 10% owner | May 27, 2022 | Buy | +28,000 | $1.84 | $51.52K | 871,114 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.